Humacyte Inc [NASDAQ: HUMA] jumped around 0.41 points on Tuesday, while shares priced at $2.57 at the close of the session, up 18.98%.
Humacyte Inc stock is now -54.67% down from its year-to-date (YTD) trading value. HUMA Stock saw the intraday high of $2.795 and lowest of $2.35 per share. The company’s 52-week high price is 9.79, which means current price is +123.48% above from all time high which was touched on 01/02/25.
Compared to the average trading volume of 3.95M shares, HUMA reached a trading volume of 14385472 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Humacyte Inc [HUMA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HUMA shares is $9.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HUMA stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Humacyte Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 14, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $12 to $15. The new note on the price target was released on December 20, 2024, representing the official price target for Humacyte Inc stock. Previously, the target price had yet another raise to $6, while H.C. Wainwright analysts kept a Buy rating on HUMA stock. On August 14, 2023, analysts increased their price target for HUMA shares from 2.75 to 3.50.
The Price to Book ratio for the last quarter was 11.06, with the Price to Cash per share for the same quarter was set at 0.41.
How has HUMA stock performed recently?
Humacyte Inc [HUMA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 22.97. With this latest performance, HUMA shares dropped by -1.91% in over the last four-week period, additionally sinking by -50.39% over the last 6 months – not to mention a drop of -49.11% in the past year of trading.
Humacyte Inc [HUMA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Humacyte Inc [HUMA] shares currently have an operating margin of -21470.79% and a Gross Margin at -1335.59%. Humacyte Inc’s Net Margin is presently recorded at -15481.62%.
Return on Equity for this stock declined to -49.40%, with Return on Assets sitting at -49.40%.
Insider trade positions for Humacyte Inc [HUMA]
There are presently around $39.87%, or 49.94% of HUMA stock, in the hands of institutional investors. The top three institutional holders of HUMA stocks are: BLACKROCK INC. with ownership of 7.14 million shares, which is approximately 5.9912%. VANGUARD GROUP INC, holding 4.73 million shares of the stock with an approximate value of $$22.7 million in HUMA stocks shares; and VANGUARD GROUP INC, currently with $$13.77 million in HUMA stock with ownership which is approximately 2.4071%.
